NCT07170761

Biomarkers and Event Patterns of Vascular Disease in Hemodialysis

Cross-sectional Biomarker Study for Vascular Calcification in Hemodialysis Patients

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 475 (actual)
• Sponsor: Medical University of Graz · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

Parathyroid hormone (PTH) remains the central biomarker to classify CKD-metabolic bone disease (CKD-MBD) in hemodialysis patients. While PTH-values are known to be associated with adverse outcomes, interventional studies have failed to show a benefit of pharmacological modulation of PTH levels on hard clinical outcomes. To address this gap, the investigators explored alternative markers of bone metabolism, vascular calcification and inflammation in association to prospective event patterns.

Conditions

• Vascular Disease
• CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder

Timeline

• Start date: 2022-10-15
• Primary completion: 2027-12-31
• Completion: 2027-12-31
• First posted: 2025-09-12
• Last updated: 2026-03-05

Locations

1 site across 1 country: Austria